Stock Financial Ratios, Dividends, Split History

MRNS / Marinus Pharmaceuticals, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price7.49
Volume736,900.00
Market Cap ($M)303.09
Enterprise Value ($M)121.26
Book Value ($M)53.12
Book Value / Share1.31
Price / Book5.23
NCAV ($M)51.81
NCAV / Share1.28
Price / NCAV5.86
Share Statistics
Common Shares Outstanding 40,520,705
Preferred Stock Shares Outstanding 0
Common Stock Shares Outstanding 40,520,705
Scoring Models
Piotroski F-Score1.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.33
Return on Assets (ROA)-0.60
Return on Equity (ROE)-0.88
Balance Sheet (mrq) ($M)
Assets55.03
Liabilities1.91
Quick Ration/a
Current Ratio29.94
Income Statement (mra) ($M)
Operating Income-19.04
Net Income-18.90
Earnings Per Share Basic And Diluted-0.80
Cash Flow Statement (mra) ($M)
Cash From Operations-18.82
Cash from Investing-21.42
Cash from Financing-21.42
Identifiers and Descriptors
CUSIP56854Q101
Central Index Key (CIK)1267813

Split History

Stock splits are used by Marinus Pharmaceuticals, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon
MRNS: Marinus Pharmaceuticals Analysis and Research Report

2018-04-27 - Asif

Overview Marinus Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. The company's clinical stage product candidate, ganaxolone, is a positive allosteric modulator of GABAA being developed in three different dose forms: intravenous (IV), capsule and liquid. The multiple dose forms are intended to maximize the therapeutic range of ganaxolone for adult and pediatric patient populations, in acute and chronic care, and both in-patient and self-administered settings. Ganaxolone exhibits anti-seizure, anti-anxiety and anti-depressive actions via its effects on synaptic and extrasynaptic GABAA receptors. The company's Pipeline Marinus Pharmaceuticals is developing ganaxolone to treat children suffering from rare epilepsies and both adults and children suffering from other neuropsychiatric conditions where there is a mechanistic rationale for ganaxolo...

Related Articles

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

STML: Stemline Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Stemline Therapeutics was incorporated under the laws of the State of Delaware in August 2003. Stemline Therapeutics is a clinical stage biopharmaceutical company focused on discovering, acquiring, developing and potentially commercializing innovative oncology therapeutics that target difficult to treat cancers. The company's clinical pipeline includes: SL-401, SL-801, and SL-701. SL-401 pivotal data; plans for registration and potential commercialization: SL-401 has completed a pivotal trial in patients with blastic plasmacytoid dendritic cell neoplasm, or BPDCN, and has successfully met the primary endpoint of the trial. SL-401 is a targeted therapy directed to the interleukin-3 receptor-a, or CD123. SL-401 was granted breakthrough therapy designation, or BTD, by the U.S. Food and Drug Administration, or FDA, for the treatment of patients with BPDCN. Based on the trial results and other data, the company expect to complete submission of a rolling Biologics License...

Related News Stories

GW Pharmaceuticals: Value Beyond Epidiolex?

2018-06-04 seekingalpha
GW has Sativex ready for a Phase 3 study in an indication that already has approval in several countries outside of the US. (120-0)

How To Use Probabilities In Investing: Open Sources

2018-05-11 seekingalpha
(In whose favor are the odds of this particular game, hmm? Image by Own work, CC BY-SA 3.0, source) (83-0)

BRIEF-Marinus Pharmaceuticals Reports Quarterly Loss Per Share $0.15

2018-05-02 reuters
* MARINUS PHARMACEUTICALS INC - AT MARCH 31, 2018, HAD CASH, CASH EQUIVALENTS AND INVESTMENTS OF $52.0 MILLION, COMPARED TO $58.4 MILLION AT DECEMBER 31, 2017 (71-0)

Ovid Therapeutics: Beaten Down IPO With Upcoming 2018 Catalysts

2018-05-01 seekingalpha
Data from the phase 2 STARS trial for OV101 in Angelman’s syndrome is expected in Q3, 2018. (204-0)

U.S. Biotech/Pharma Sector Daily Observations Letter: March 15, 2018

2018-03-16 seekingalpha
The small pullback in the U.S. biotechnology indexes (IBB) (XBI) after a run-up from the recent correction lows looks almost complete and we expect the uptrend to resume soon. (143-0)

CUSIP: 56854Q101